Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary artery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200727048226N1

Enrollment

Registered

2020-08-06

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction.

Interventions

Intervention group: each patient recieves one 10 mg tablet of empagliflozin from abidi institute or placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: non-diabetic patients with PPCI on LAD that are SVD: non-diabetic patients definition: 1-HbA1C<6.5 2-history of non-diabetes 3-twice FBS<100 if two of three of these exist patient is eligible for entery of trial

Exclusion criteria

Exclusion criteria: 1-History of serious hypersensitivity to empagliflozin or any component of the formulation; -Severe renal impairment (eGFR 70% or with SVD of LCX or RCA 3-patients 4- diabetic patients

Design outcomes

Primary

Measure	Time frame
Efficacy of empagliflozin on cardiac function in non- diabetic patients admitted in Tehran Heart Center after primary PCI on LAD. Timepoint: echocardiography and blood sampling will be done 48 hours and after three months of reciveing medicine. Method of measurement: three dimentional echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsara hosseini

Tehran University of Medical Sciences

hosseinisa1990@gmail.com00921865829828

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026